Persistent smell and taste disorders following COVID-19 vaccination: A report of three cases and review of the literature

Abstract

Persistent smell and taste disorders following COVID-19 vaccination are rare adverse effects. Herein, we reported three cases in which patients developed smell and taste disorders 9 - 20 days after receiving their second dose of the AstraZeneca/Oxford COVID-19 vaccine in 2021. These symptoms persisted for 1 - 3 years. All patients underwent nasal endoscopy, imaging of the nasal and olfactory structures, as well as Sniffin’ Odor along with flavor and taste identification tests. Case 1 was a 37-year-old male who presented in December 2022 with persistent dysgeusia for 18 months. Case 2 was a 40-year-old male who presented in February 2023 with persistent anosmia and parosmia for 20 months. Case 3 was a 48-year-old male who presented in August 2024 with persistent hyposmia for 3 years. These persistent disorders may be due to immune responses triggered by the vaccine, potentially affecting the olfactory neuroepithelium. Recognition and reporting of such adverse effects are important to acknowledge among physicians and for future studies and treatment trials targeting related disorders.

Keywords

COVID-19 vaccine / Anosmia / Ageusia / Parosmia / Dysgeusia

Funding

None.

Conflict of interest

The authors declare that they have no competing interests.

References

[1] Francis AI, Ghany S, Gilkes T, Umakanthan S. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad Med J. 2022; 98(1159):389-394. doi: 1136/postgradmedj-2021-140654

[2] COVID-19 mRNA Pfizer- BionTech Vaccine Analysis Print; 2021. Available from: https://assets.publishing.service.gov.uk/media/628e3cd3d3bf7f1f3b19efd2/foi-21-1345-22.pdf[2021 Apr 30]

[3] COVID-19 AstraZeneca Vaccine Analysis Print; 2021. Available from: https://assets.publishing.service.gov.uk/media/65f16ea8133c220011cd39e0/foi-23-670-pdf-attachment--17-.pdf [2021 Dec 04]

[4] Klugar M, Riad A, Mekhemar M, et al. Side effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers. Biology (Basel). 2021; 10(8):752. doi: 10.3390/biology10080752

[5] Riad A, Põld A, Kateeb E, Attia S. Oral adverse events following COVID-19 vaccination: Analysis of VAERS reports. Front Public Health. 2022;10:952781. doi: 10.3389/fpubh.2022.952781

[6] Zamzami OS, Kabli AF, Alhothali AS, et al. Post-COVID-19 vaccine parosmia: A case report. Cureus. 2021; 13(12):e20292. doi: 10.7759/cureus.20292

[7] Fantin F, Frosolini A, Tundo I, et al. A singular case of hyposmia and transient audiovestibular post-vaccine disorders: Case report and literature review. Transl Neurosci. 2022; 13(1):349-353. doi: 10.1515/tnsci-2022-0250

[8] Ogata S, Ishii Y, Asano K, et al. Sensory ataxic Guillain- Barré syndrome with dysgeusia after mRNA COVID-19 vaccination. Intern Med. 2022; 61(11):1757-1760. doi: 10.2169/internalmedicine.8967-21

[9] Barter K, Bagnato F. Olfactory hallucinations following COVID-19 vaccination. Fed Pract. 2023; 40(9):1-3. doi: 10.12788/fp.0410

[10] Shin B, Tam AC. COVID-19 mRNA Vaccine Linked to Dysgeusia and Hyposmia:A Case Report. Henry Ford Jackson Hospital Research Symposium; 2024. Available from: https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?article=1011&context=hfjhrs2024[2025 Jan 15]

[11] Keir G, Maria NI, Kirsch CF. Unique imaging findings of neurologic phantosmia following pfizer-biontech COVID-19 vaccination: A case report. Top Magn Reson Imaging. 2021; 30(3):133-137. doi: 10.1097/RMR.0000000000000287

[12] Hamed SA, Ahmed MA. The effectiveness of cerebrolysin, a multi-modal neurotrophic factor, for treatment of post- COVID-19 persistent olfactory, gustatory and trigeminal chemosensory dysfunctions: A randomized clinical trial. Expert Rev Clin Pharmacol. 2023; 16(12):1261-1276. doi: 10.1080/17512433.2023.2282715

[13] Hamed SA, Kamal-Eldeen EB, Ahmed MA. Evaluation of children and adults with post-COVID-19 persistent smell, taste and trigeminal chemosensory disorders: A hospital based study. World J Clin Pediatr. 2023; 12(3):133-150. doi: 10.5409/wjcp.v12.i3.133

[14] Hamed SA. Post-COVID-19 persistent olfactory, gustatory, and trigeminal chemosensory disorders: Definitions, mechanisms, and potential treatments. World J Otorhinolaryngol. 2023; 10(2):4-22. doi: 10.5319/wjo.v10.i2.4

[15] Lee WS, Wheatley AK, Kent SJ, Dekosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020; 5(10):1185-1191. doi: 10.1038/s41564-020-00789-5

[16] Farsalinos K, Eliopoulos E, Leonidas DD, Papadopoulos GE, Tzartos S, Poulas K. Nicotinic cholinergic system and COVID-19: In silico Identification of an interaction between SARS-CoV-2 and nicotinic receptors with potential therapeutic targeting implications. Int J Mol Sci. 2020; 21(16):5807. doi: 10.3390/ijms21165807

[17] Tracey KJ. The inflammatory reflex. Nature. 2002; 420(6917):853-859. doi: 10.1038/nature01321

[18] Coelho P, Paula A, Martins IV, et al. Combined central and peripheral demyelination after COVID-19 vaccination. J Neurol. 2022; 269(9):4618-4622. doi: 10.1007/s00415-022-11188-7

[19] Yao L, Yi X, Pinto JM, et al. Olfactory cortex and olfactory bulb volume alterations in patients with post-infectious olfactory loss. Brain Imaging Behav. 2018; 12(5):1355-1362. doi: 10.1007/s11682-017-9807-7

[20] Frosolini A, Parrino D, Fabbris C, et al. Magnetic resonance imaging confirmed olfactory bulb reduction in long COVID-19: Literature review and case series. Brain Sci. 2022; 12(4):430. doi: 10.3390/brainsci12040430